Positive new Sativex® data from Germany presented at ECTRIMS

A cannabis derived drug which has been approved in some countries to treat muscle spasticity.

Positive new Sativex® data from Germany presented at ECTRIMS

Postby MSUK » Thu Oct 11, 2012 10:45 pm

Image

Almirall S.A. announced that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month's treatment with Sativex®(THC:CBD) oromucosal spray reduces moderate to severe multiple sclerosis spasticity (MSS) by 20% or more in 4 out of 10 patients previously unresponsive to conventional therapies. After three months, the improvement observed was 30% or more. Overall, 55% of the initial patients were eligible for continuing treatment beyond the third month.

This prospective, observational study is presented today at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2212
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Sativex

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service